Malignant progression of cancer is supported largely by cues received through altered cell-cell and cell-matrix interactions that promote the metastatic potential of malignant cells. Integrins, a class of cell-surface adhesive receptors that exist as obligate α-β heterodimers, mediate many of these interactions (1) . Oncogenic transformation can directly or indirectly increase the abundance of certain integrin subunits and decrease that of other integrin subunits, thereby changing not only the absolute number of available integrins but also their α-β composition. Consequently, the integrin repertoire is changed or "switched" to support cancer initiation and progression. In many instances, integrins that secure adhesion to the basement membrane are lost, whereas the abundance of integrins that stimulate cell survival, migration, proliferation, and invasion are increased. Although the specifi c nature of integrin switching varies among cancers, α2β1 and α3β1 integrins suppress cancer progression and metastasis, whereas α5β1 and β3 and β4 integrins can promote metastatic progression (1, 2) . Integrin switching is central to epithelialmesenchymal transition (EMT), a process in which polarized epithelial cells transition to a migratory mesenchymal-like state during malignant progression. However, the mechanism by which integrin switching contributes to metastatic progression remains poorly understood.
The β1 integrin subunit pairs with at least 11 α subunits to produce heterodimers that mediate adhesion to a wide variety of ligands, including matrix molecules (such as collagen, laminin, and fi bronectin, among others) and cell surface proteins, such as E-cadherin and vascular cell adhesion molecules (1). Studies using in vitro and in vivo orthotopic or xenograft models indicate that the β1 integrins mediate drug resistance and stimulate metastasis in gastric, ovarian, and lung cancers (1) . Similarly, animals with targeted deletion of the β1-encoding gene in mammary epithelium fail to develop cancer, suggesting that the β1 integrins are essential for cancer initiation (3). However, the loss of specifi c β1 integrin species may be important in progression to metastasis. Transgenic deletion of α2β1 integrin increases metastasis in the spontaneous MMTV-Neu tumor model, whereas the loss of α3β1 promotes metastasis in models of prostate cancer (2, 4) . Decreased abundance of these β1 species in human patients affi rms their clinical relevance in disease progression. Consequently, understanding how the loss of β1 integrin functions contributes to metastatic progression has both mechanistic and therapeutic implications.
In the 11 February 2014 issue of Science Signaling, Truong et al. reported that functional inhibition or knockdown of the β1 integrin enhanced metastatic lung colonization by promoting EMT through activation of the transforming growth factor-β (TGF-β) signaling network (Fig. 1A) . This converted the migratory behavior of human and mouse triple-negative breast cancer cells (TNBCs) from collective to single-cell movement and enhanced metastatic lung colonization by decreasing the expression of the gene encoding E-cadherin through a pathway involving microRNA-200 (miR-200) and the transcription factor ZEB2 (5).
These intriguing results are reminiscent of fi ndings from Parvani et al. who observed a compensatory increase in β3 integrin expression upon β1 integrin inhibition in breast cancer (6) (Fig. 1B) observed that inhibition or knockdown of β1 integrin governed a trade-off between tumor cell proliferation and cell motility and dissemination, leading to reduced growth at both the primary and secondary locations while promoting systemic dissemination. Those fi ndings reaffi rm the well-established requirement of proliferative signals from β1 integrin and highlight the integration of proliferation and migration. The correlation to a β1/β3 switch to this behavior was also observed by Liu et al., who found that Myc overexpression supported tumor proliferation but not invasion and motility because of repressed expression of the gene encoding β3 integrin (7). Together, these fi ndings indicate that both loss of β1 integrin and gain of β3 integrin are required to provide metastatic competence.
Observations by Truong et al. suggest that integrins are potent therapeutic targets in our attempts to counter the proliferative and invasive signals. However, it will be important to consider the balance of signal integration through β1 and β3 because simply inhibiting either alone could inadvertently drive dissemination or tumor growth.
These fi ndings also offer a new perspective on the infl uence of integrin switching in EMT and tumor metastasis. TGF-β famously plays a dichotomous role in cancer, acting as a tumor suppressor in early carcinomas and a promoter of EMT and metastasis in more advanced cancers. Perhaps integrin switching from β1 to β3 integrin directs the biological response to activation of the TGF-β signaling network. Although conclusive evidence is not yet available, matrix interactions are clearly relevant as Leight et al. have recently demonstrated that matrix rigidity regulates the phosphoinositide 3 kinase/AKT-dependent switch between TGF-β-induced apoptosis and TGF-β-induced EMT (8) . Additionally, direct interaction between TGF-β and both β1 and β3 integrins have been documented, indicating the potential for differential complex-specifi c signaling (6).
Truong et al. observed that β1 integrin inhibition potentiated TGF-β-induced EMT only in TNBC. As TNBCs present clinically with a high incidence of lymph node metastasis even among small tumors, the trade-off between proliferation and metastasis may explain an important aspect of TNBC biology. New TNBC subclassifi cation schema proposed by Lehman et al. may help to further identify the specifi c oncogenic contexts where Truong's integrin-TGF-β prometastatic switch may be relevant (9) . Although there are several distinct properties that defi ne the aggressive nature of TNBC, it is known to have particularly high p53 mutation status. Mutant p53 promotes both random cell motility and increased invasiveness by accelerating the recycling of β1 integrins to the plasma membrane, where the integrin complex may serve as a metastatic engine (10, 11) . Upon phosphorylation, wildtype p53 binds Smads to support cytostatic TGF-β signaling. In contrast, complexes formed between mutant-p53 and Smads inhibit p63, a p53 family member that inhibits TGF-β-induced metastasis (12) . Integration of the integrin-TGF-β prometastatic switch with p53 status may explain the divergent cellular response to TGF-β and thus warrants closer scrutiny.
In summary, the work of Truong et al. provides a mechanism by which loss of β1 integrin elicits a prometastatic switch in later stages of disease progression. Further characterization of β-integrin switching will require elucidation of the specifi c α-β integrin heterodimer distribution and the role of ligand binding. Identifying the nature of the molecular interactions and the infl uence of a specifi c oncogenic context, including the status of driver mutations, such as those in Myc and p53, will defi ne the next phase in integrin cancer biology.
